HL

Yuqin Song | ASH 2018 | Tislelizumab (BGB-A317) in relapsed/refractory classical Hodgkin lymphoma

L: English
Watch Mandarin version

60th ASH Annual Meeting & Exposition, December 1-4 2018, San Diego, CA

Yuqin Song, Peking University Cancer Hospital, Beijing, CN

Interview Topic: Tislelizumab (BGB-A317) in relapsed/refractory classical Hodgkin lymphoma

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!